### ü´Å Pulmonology: Œ±1-Antitrypsin Deficiency Diagnosis

#### ‚úÖ True Statements
1. **Œ±1-Antitrypsin deficiency** should be considered in all patients with **chronic obstructive pulmonary disease (COPD)** who are **younger than 45 years**.
2. **Œ±1-Antitrypsin deficiency** should be considered in patients with **COPD** who have a **strong family history of COPD**.
3. **Œ±1-Antitrypsin deficiency** should be considered in patients with **COPD** who have **no identifiable COPD risk factors**.
4. **Œ±1-Antitrypsin deficiency** is associated with a pattern of **basilar emphysema** on chest imaging.

#### üí¨ Extra
4. On posteroanterior chest radiograph, **absence of lung markings in the lower lobes** is consistent with basilar emphysema and is suggestive of **Œ±1-antitrypsin deficiency**.

#### üè∑Ô∏è Tags
#Pulmonology #AmbulatoryCare #COPD #Alpha1AntitrypsinDeficiency #Emphysema

#### üìö Reference
Stoller JK, Aboussouan LS. Œ±1-Antitrypsin deficiency. *Lancet*. 2005;365(9478):2225-2236. PMID: 15978931 doi:10.1016/S0140-6736(05)66781-5

#### üÜî Question ID
PMVDX24006

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Airways Disease, Chronic Obstructive Pulmonary Disease, COPD Disease Assessment

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî COPD Disease Assessment
1. Assessment of **chronic obstructive pulmonary disease (COPD)** includes determining the **severity of symptoms** and the **risk of acute exacerbation**.
2. Validated tools to assess **COPD symptom severity** include the **COPD Assessment Test (CAT)**, the **modified Medical Research Council (mMRC) scale**, the **St. George's Respiratory Questionnaire**, and the **Clinical COPD Questionnaire**.
3. The **Clinical COPD Questionnaire** is also used to **screen for COPD symptoms**.
4. Factors that predict a **high risk of recurrent COPD exacerbations** include **FEV1 less than 50% of predicted**, **two or more acute exacerbations in the past year**, and **a history of hospitalization for an acute exacerbation**.
5. A formal assessment of **COPD disease severity** can be obtained using the **GOLD model**, which incorporates **symptom severity (CAT or mMRC)** and **history of acute exacerbations**.
6. The **COPD Assessment Test (CAT)** has a **total score range of 0 to 40**, with **higher scores indicating greater symptom severity**.
7. The degree of **airflow obstruction** measured by **spirometry** and the presence of **comorbid conditions** are additional markers of **COPD disease severity**.
8. Clinicians should assess for **comorbidities associated with COPD** because they indicate **higher morbidity and mortality** and require appropriate treatment.
9. **Pulse oximetry at rest and with exertion** should be used in COPD to determine the **need for supplemental oxygen**.
10. **Arterial blood gases** should be measured in COPD to assess for **hypercapnia** in patients with **low FEV1**, **change in mental status**, **acute exacerbation**, **elevated serum bicarbonate level**, or **oxygen saturation less than 92%** on pulse oximetry.
11. An **Œ±1-antitrypsin level** should be obtained **once in all patients with COPD**.
12. A **pattern of basilar emphysema**, **associated liver disease**, **panniculitis**, or a **strong family history of emphysema** in patients with COPD suggests possible **Œ±1-antitrypsin deficiency**.
13. Clinical features such as **basilar emphysema**, **liver disease**, **panniculitis**, or **family history** are **not sufficiently sensitive to rule out Œ±1-antitrypsin deficiency without testing**.

#### üí¨ Extra
5. The GOLD model combines symptom scores with exacerbation history to stratify severity and direct therapy.
11. Screening for **Œ±1-antitrypsin deficiency** is universal in COPD, regardless of risk factors.
13. Diagnostic testing is required because clinical predictors alone lack sensitivity.

#### üè∑Ô∏è Tags
#COPD #Pulmonology #DiseaseAssessment #Alpha1AntitrypsinDeficiency #GOLD #Exacerbations #Comorbidities #CAT #mMRC #Spirometry

---

#### üóæ Supplemental Tables

<!-- CAT‚Ñ¢ Assessment -->
<table>
  <caption><strong>CAT‚Ñ¢ Assessment</strong></caption>
  <thead>
    <tr>
      <th colspan="4">For each item below, place a mark (x) in the box that best describes you currently. Be sure to only select one response for each question.</th>
    </tr>
    <tr>
      <th>&nbsp;</th>
      <th>[0] [1] [2] [3] [4] [5]</th>
      <th>&nbsp;</th>
      <th>Score</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><em>Example:</em> I am very happy</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>I am very sad</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>I never cough</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>I cough all the time</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>I have no phlegm (mucus) in my chest at all</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>My chest is completely full of phlegm (mucus)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>My chest does not feel tight at all</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>My chest feels very tight</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>When I walk up a hill or one flight of stairs I am not breathless</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>When I walk up a hill or one flight of stairs I am very breathless</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>I am not limited doing any activities at home</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>I am very limited doing activities at home</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>I am confident leaving my home despite my lung condition</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>I am not at all confident leaving my home because of my lung condition</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>I sleep soundly</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>I don't sleep soundly because of my lung condition</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>I have lots of energy</td>
      <td>[0] [1] [2] [3] [4] [5]</td>
      <td>I have no energy at all</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td colspan="3" style="text-align:right;"><strong>Total Score:</strong></td>
      <td>&nbsp;</td>
    </tr>
  </tbody>
</table>
<p><em>Reference: Jones PW, Harding G, Berry P, et&nbsp;al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648-54. PMID: 19720809 doi:10.1183/09031936.00102509</em></p>
<p><em>Reproduced with permission of the Global Initiative for Chronic Obstructive Lung Disease. ¬© 2023, 2024, Global Initiative for Chronic Obstructive Lung Disease, available from www.goldcopd.org, published in Deer Park, IL, USA.</em></p>

<!-- Classification of COPD Severity by GOLD Patient Category -->
<table>
  <caption><strong>Classification of COPD Severity by GOLD Patient Category</strong></caption>
  <thead>
    <tr>
      <th>Patient Category</th>
      <th>Characteristics</th>
      <th>Exacerbations Per Year</th>
      <th>CAT Score</th>
      <th>mMRC Score</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>A</td>
      <td>Low risk, fewer symptoms</td>
      <td>‚â§1, no hospitalization</td>
      <td>&lt;10</td>
      <td>0-1</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Low risk, more symptoms</td>
      <td>‚â§1, no hospitalization</td>
      <td>‚â•10</td>
      <td>‚â•2</td>
    </tr>
    <tr>
      <td>E</td>
      <td>High risk</td>
      <td>‚â•2 or ‚â•1 with hospitalization</td>
      <td>Any</td>
      <td>Any</td>
    </tr>
  </tbody>
</table>
<p><em>CAT = COPD Assessment Test; GOLD = Global Initiative for Chronic Obstructive Lung Disease; mMRC = Modified Medical Research Council dyspnea scale.</em></p>
<p><em>Information from Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.</em></p>

<!-- GOLD Grades and Severity of Airflow Obstruction in COPD -->
<table>
  <caption><strong>GOLD Grades and Severity of Airflow Obstruction in COPD<sup>a</sup></strong></caption>
  <thead>
    <tr>
      <th>Category</th>
      <th>Severity</th>
      <th>Spirometry</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GOLD 1</td>
      <td>Mild</td>
      <td>FEV<sub>1</sub> ‚â•80% of predicted</td>
    </tr>
    <tr>
      <td>GOLD 2</td>
      <td>Moderate</td>
      <td>50% ‚â§ FEV<sub>1</sub> &lt;80% of predicted</td>
    </tr>
    <tr>
      <td>GOLD 3</td>
      <td>Severe</td>
      <td>30% ‚â§ FEV<sub>1</sub> &lt;50% of predicted</td>
    </tr>
    <tr>
      <td>GOLD 4</td>
      <td>Very severe</td>
      <td>FEV<sub>1</sub> &lt;30% predicted</td>
    </tr>
  </tbody>
</table>
<p><em>GOLD = Global Initiative for Chronic Obstructive Lung Disease.</em></p>
<p><em><sup>a</sup>In patients with FEV<sub>1</sub>/FVC less than 0.7, based on postbronchodilator FEV<sub>1</sub>.</em></p>
<p><em>Reproduced with permission of the Global Initiative for Chronic Obstructive Lung Disease, available from www.goldcopd.org, published in Deer Park, IL, USA.</em></p>

---

### üìò Supplemental Table Derivations

#### ‚úÖ True Statements ‚Äî CAT‚Ñ¢ Assessment
1. The **COPD Assessment Test (CAT)** includes **eight symptom domains**: cough, phlegm, chest tightness, breathlessness, activity limitation, confidence leaving home, sleep, and energy.
2. The **COPD Assessment Test (CAT)** uses a **0 to 5 scale per item**, with higher scores reflecting **worse symptoms**.
3. The **COPD Assessment Test (CAT)** total score ranges from **0 to 40**, with **higher values indicating greater disease burden**.

#### ‚úÖ True Statements ‚Äî Classification of COPD Severity by GOLD Patient Category
4. In the **GOLD classification**, **Category A** is defined as **‚â§1 exacerbation per year without hospitalization**, **CAT <10**, and **mMRC 0‚Äì1**.
5. In the **GOLD classification**, **Category B** is defined as **‚â§1 exacerbation per year without hospitalization**, **CAT ‚â•10**, or **mMRC ‚â•2**.
6. In the **GOLD classification**, **Category E** is defined as **‚â•2 exacerbations per year** or **‚â•1 exacerbation requiring hospitalization**, regardless of **CAT or mMRC scores**.

#### ‚úÖ True Statements ‚Äî GOLD Grades and Severity of Airflow Obstruction in COPD
7. **GOLD 1 (mild COPD)** is defined by **FEV1 ‚â•80% of predicted** in patients with **FEV1/FVC <0.7**.
8. **GOLD 2 (moderate COPD)** is defined by **FEV1 50‚Äì79% of predicted** in patients with **FEV1/FVC <0.7**.
9. **GOLD 3 (severe COPD)** is defined by **FEV1 30‚Äì49% of predicted** in patients with **FEV1/FVC <0.7**.
10. **GOLD 4 (very severe COPD)** is defined by **FEV1 <30% of predicted** in patients with **FEV1/FVC <0.7**.

#### üí¨ Extra
1. Each CAT domain is scored independently and added to calculate the total score.
4. GOLD Category A represents patients with low risk and fewer symptoms.
5. GOLD Category B represents patients with low risk but more symptoms.
6. GOLD Category E represents high risk regardless of symptom severity.
7. GOLD grades are based on **post-bronchodilator FEV1**.

#### üè∑Ô∏è Tags
#COPD #Pulmonology #CAT #GOLD #Spirometry #Exacerbations #DiseaseAssessment
